Staar Surgical Company (STAA) Stock Price, Quote & News

Company Profile

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, and sells implantable lenses for the eye and accessory delivery systems to deliver the lenses into the eye. The company provides implantable Collamer lens product family (ICLs) and laser-based procedures, such as LASIK to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia. It serves its products to health care providers, including ophthalmic surgeons, vision and surgical centers,...

Industry: Medical Instruments & Supplies

Sector: Healthcare

Phone: 626 303 7902

Fax: 626 359 8402

Website: www.staar.com

Address:

25510 Commercentre Drive, Lake Forest, United States

AStrokeOfLuck Dec. 12 at 7:33 PM

$STAA

0 · Reply

smartkarma Dec. 12 at 2:50 PM

$STAA | STAAR Surgical Faces Shareholder Activism and Alcon's Revised Bid Amidst China Sales Recovery and Strategic Uncertainty "STAAR Surgical's China sales rebounded to 60% of normalized levels, supporting activist investors' opposition to Alcon's takeover offer." - Special Situation Investments (Special Situation Investments) Read more: https://www.smartkarma.com/insights/staar-surgical-faces-shareholder-activism-and-alcon-s-revised-bid-amidst-china-sales-recovery-and-strategic-uncertainty

0 · Reply

BuyOnRedSellOnGreen Dec. 11 at 7:15 PM

$STAA scared

0 · Reply

StockBraker Dec. 11 at 12:28 PM

$STAA https://www.businesswire.com/news/home/20251210793955/en/Broadwood-Partners-Comments-on-STAAR-Surgical-Board-Dissent-on-the-Revised-Sale-to-Alcon

1 · Reply

JarvisFlow Dec. 10 at 8:15 PM

Wells Fargo has updated their rating for Staar Surgical ( $STAA ) to Equal-Weight with a price target of 30.75.

0 · Reply

MaverikIT Dec. 10 at 7:05 PM

$STAA $ALC - reject the deal$

0 · Reply

topstockalerts Dec. 10 at 7:00 PM

STAAR Surgical shares fell Wednesday as Yunqi Capital became the latest major investor to oppose Alcon’s raised $30.75-per-share takeover offer. The $1.6 billion bid, increased to ease shareholder backlash, now faces significant resistance ahead of the Dec. 19 vote. Yunqi, which owns 5.1%, urged investors to reject the deal, arguing—like top holder Broadwood—that STAAR is recovering and at a strategic turning point, making a sale premature. It cited improving operating trends and normalizing inventory in China. The firm also dismissed the 30-day go-shop as too short, restrictive, and lacking transparency due to NDA terms that could deter rival bidders. Yunqi said the 74% premium over the 90-day VWAP overstates value relative to STAAR’s long-term potential, joining Broadwood (30.2%) in rejecting the bid. $STAA $ALC

0 · Reply

JarvisFlow Dec. 10 at 6:13 PM

Canaccord Genuity updates rating for Staar Surgical ( $STAA ) to Hold, target set at 28 → 30.75.

0 · Reply

RUNNINWILD Dec. 10 at 5:19 PM

$STAA market appears to be pricing in no other offer and Alcon walking away

0 · Reply

IN0V8 Dec. 10 at 4:46 PM

$STAA Wells Fargo raises target price to $30.75 from $28

0 · Reply

Market Cap	1.20B
Revenue (ttm)	313.90M
Net Income (ttm)	-20.21M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-6.44%
Debt to Equity Ratio	0.00

Volume	1,974,100
Avg Vol	1,178,762
Day's Range	N/A - N/A
Shares Out	49.74M
Stochastic %K	24%
Beta	1.01
Analysts	Hold
Price Target	$27.19